AstraZeneca India Posts 31% Revenue Surge in Q2

14 Nov 2024 , 10:48 AM

AstraZeneca Pharma India reported its financial results for Q2 FY25, showing a notable revenue increase.

Revenue from operations surged by 31% to ₹408 Crore in Q2, compared to the same period last year. For the first half (H1) of FY25, the revenue rose to ₹795.5 Crore, driven by growth in oncology, biopharmaceuticals, and rare disease segments. Profit before exceptional items and tax for Q2 stood at ₹51 Crore, with a profit after tax of ₹38.4 Crore, recovering from a net loss of ₹11.8 Crore in Q1.

CFO Bhavana Agrawal highlighted the company’s steady growth in India, attributing it to consistent progress in oncology, biopharmaceuticals, and rare diseases. Country President and Managing Director Dr. Sanjeev Panchal emphasized AstraZeneca’s commitment to healthcare innovation in India, focusing on expanding access to advanced therapies and strengthening healthcare systems.

AstraZeneca introduced two new products, palivizumab and tremelimumab injections, into the Indian market, receiving regulatory approval from the Drugs Controller General of India (DCGI).

The company’s “Growth Through Innovation” strategy is aimed at meeting unmet patient needs in India, underscoring a commitment to science-driven healthcare solutions.